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Research
AbstrACt
Objectives To describe the characteristics of children 
and adults with incident type 1 diabetes in contemporary, 
multiethnic UK, focusing on differences between the islet 
autoantibody negative and positive.
Design Observational cohort study.
setting 146 mainly secondary care centres across 
England and Wales.
Participants 3312 people aged ≥5 years were recruited 
within 6 months of a clinical diagnosis of type 1 diabetes 
via the National Institute for Health Research Clinical 
Research Network. 3021 were of white European ethnicity 
and 291 (9%) were non-white. There was a small male 
predominance (57%). Young people <17 years comprised 
59%.
Main outcome measures Autoantibody status and 
characteristics at presentation.
results The majority presented with classical osmotic 
symptoms, weight loss and fatigue. Ketoacidosis was 
common (42%), especially in adults, and irrespective of 
ethnicity. 35% were overweight or obese. Of the 1778 
participants who donated a blood sample, 85% were 
positive for one or more autoantibodies against glutamate 
decarboxylase, islet antigen-2 and zinc transporter 8. 
Presenting symptoms were similar in the autoantibody-
positive and autoantibody-negative participants, as 
was the frequency of ketoacidosis (43%vs40%, P=0.3). 
Autoantibody positivity was less common with increasing 
age (P=0.0001), in males compared with females 
(82%vs90%, P<0.0001) and in people of non-white 
compared with white ethnicity (73%vs86%, P<0.0001). 
Body mass index was higher in autoantibody-negative 
adults than autoantibody-positive adults (median, IQR 
25.5, 23.1–29.2vs23.9, 21.4–26.7 kg/m2; P=0.0001). 
Autoantibody-negative participants were more likely to 
have a parent with diabetes (28%vs16%, P<0.0001) and 
less likely to have another autoimmune disease (4%vs8%, 
P=0.01).
Conclusions Most people assigned a diagnosis of type 1 
diabetes presented with classical clinical features and islet 
autoantibodies. Although indistinguishable at an individual 
level, autoantibody-negative participants as a group 
demonstrated features more typically associated with 
other diabetes subtypes.
trial registration number ISRCTN66496918; Pre-results.
IntrODuCtIOn 
Type 1 diabetes (T1D) is an autoimmune 
disease that develops at any age but most 
frequently in children and young adults.1 
Autoantibodies against islet antigens are typi-
cally present before, and for a variable time 
following, diagnosis.2–6 Once initiated, beta 
cell damage classically leads to progressive 
loss of insulin secretion and a need for life-
long insulin treatment.
strengths and limitations of this study
 ► We have studied a large multiethnic cohort of adults 
and children ≥5 years with clinically diagnosed in-
cident type 1 diabetes in whom pancreatic islet au-
toantibodies were measured in a central laboratory.
 ► In routine practice, the initial assignment of a diag-
nosis of type 1 diabetes is a purely clinical one. The 
lack of further selection before inclusion in this study 
(eg, based on autoantibody status and/or genetic 
testing) renders the results of particular relevance to 
standard clinical care.
 ► Individual autoantibody-positive and autoanti-
body-negative patients were indistinguishable 
clinically, but the size and diversity of the cohort 
permitted group differences to be detected at high 
levels of statistical significance, suggesting diag-
nostic heterogeneity.
 ► As this was a volunteer study recruiting from mainly 
secondary care centres, ascertainment bias could 
have been introduced.
 ► Provision of a blood sample was optional, and auto-
antibody status was therefore available in just over 
half of the patients. Other than having a higher me-
dian age, this subgroup was representative of the 
whole cohort.
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The diagnosis of T1D is a clinical one but may be 
supported by the presence of one or more of the auto-
antibodies to islet cell antigens. In routine care, auto-
antibody status may not be available at diagnosis and 
may never be checked (management guidelines differ, 
with some not recommending their routine measure-
ment or restricting measurements to situations where 
there is clinical doubt).7–9 Previous studies suggest that 
80%–90% have detectable autoantibodies at disease 
onset,5 10 with a background autoantibody prevalence of 
around 2% in the young general population.11 Autoan-
tibody positivity may be lower in some non-white ethnic 
groups.12–16 There is however uncertainty around the 
clinical and demographic correlates of autoantibody 
status in incident disease in an unselected multiethnic 
cohort including children and adults, using well char-
acterised, validated assays. The After Diabetes Diag-
nosis REsearch Support System, supported by the 
National Institute for Health Research (NIHR) Clin-
ical Research Network (CRN), recruits people with 
incident T1D from centres across England and Wales. 
We aimed to characterise these people with reference 
to their heterogeneity, focusing on the associations 
of autoantibody status with variation in presentation 
characteristics.
MethODs
ethics approval
The project complies with the recommendations for 
research on human subjects by the 18th World Medical 
Assembly, Helsinki 1964 and later revisions and the 
International Conference on Harmonisation Guideline 
for Good Clinical Practice (Topic E6–10 June 1996). 
Protocol details have been reported previously17 and 
are therefore described in brief only.
Inclusion and exclusion criteria
People with a clinician-assigned diagnosis of T1D 
aged ≥5 years were recruited within 6 months of diag-
nosis. Written informed consent was obtained for all 
participants.
Data collection
On recruitment: demographic information; medica-
tions including insulin(s); medical history, including 
that of autoimmune disease; family history of diabetes; 
blood pressure; weight and height; HbA1c; and fasting 
or random blood glucose. A diagnosis of ketoacidosis 
was recorded if clinically assigned or if hyperglycaemia 
was accompanied by acidosis and either ketonaemia 
or ketonuria.17 Ethnicity was self-reported as one of 16 
categories.17
Project-specific blood sampling and measurement of islet 
autoantibodies
Sample donation was voluntary.17 Where collected, auto-
antibodies to glutamate decarboxylase (GADA), islet 
antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) were 
measured in sera using established radiobinding assays18 19 
in a single central laboratory. Antibodies to both major 
ZnT8 isoforms, defined by the polymorphic amino acid 
at position 325 (arginine, ZnT8RA or tryptophan and 
ZnT8WA), were measured separately. Thresholds for 
autoantibody positivity were set at the 97th percentile 
of 974 control samples for GADA, the 98th percentile 
of 500 control samples for IA-2A and the 97.5th percen-
tile of 523 healthy schoolchildren for both ZnT8RA and 
ZnT8WA. Positive autoantibody status was defined as posi-
tive for one or more of GADA, IA-2A or either form of 
ZnT8A. In the 2015 Islet Autoantibody Standardization 
Program Workshop, the assay sensitivities and specifici-
ties achieved were 74% and 96.7% for GADA, 72% and 
100% for IA-2A, 60% and 100% for ZnT8RA and 46% 
and 100% for ZnT8WA, respectively.
Data analysis
Children were defined as aged <17 years. Body mass index 
(BMI) was derived as a z-score for children using WHO 
(2007) reference data.20 As a criterion for adiposity shared 
between children and adults, we applied WHO-recom-
mended definitions of ‘normal’ weight (z-score <1, equiv-
alent percentile <84.13% for children; BMI <25 kg/m2 
for adults, both including underweight) as distinguished 
from ‘overweight’ (z-score ≥1, percentile ≥84.13% for 
children,21 BMI ≥25 kg/m2 for adults,22 both including 
obese). Parental and sibling history of diabetes was 
recorded. No attempt was made to differentiate between 
diabetes types in the family history. Variables were catego-
rised as ‘individual characteristics’ and ‘diabetes presen-
tation’. We analysed data from participants recruited 
between 1 September 2011 and 30 April 2016, with data 
querying and verification completed in November 2016.
statistical analysis
Statistical analysis was carried out using StataCorp 2013 
(Stata Statistical Software: V.13). Median and IQRs were 
used to summarise continuous variables. Categorical 
variables were summarised as percentages. The Mann-
Whitney U test and Kruskal-Wallis test were used for 
between-group comparisons of continuous variables. χ2 
testing was used for comparisons of categorical variables. 
Individual characteristics were explored as predictors of 
diabetes presentation and antibody status in univariate 
logistic and linear regression analyses. Multiple logistic 
and linear regression were used to establish the inde-
pendence of predictors. A significance level of P<0.05 
(two sided) was taken as a guide to interpretation (actual 
p values down to P<0.0001 are reported throughout).
Patient involvement
Patient and public involvement groups within the NIHR 
CRN representing people with diabetes, and repre-
senting children and young people, had input into the 
design of the patient information sheets, consent forms 
and recruitment strategies. After the start of recruitment, 
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a patient advocate group was established to have input 
into aspects of study design and conduct, such as the 
procedures for accessing the data and stored biological 
samples, and communication with and engagement of 
participants, people with T1D and healthcare profes-
sionals. The group is made up of adults with T1D and the 
parents of children with T1D. Results are disseminated to 
participants via newsletters, and other information about 
the study is published on the study website and on social 
media.
results
Overview of the cohort
Individual characteristics
Data were analysed for 3312 participants recruited with 
incident T1D (1879 (57%) males and 1946 (59%) chil-
dren from 146 centres; table 1). The slight male predom-
inance (57%) was more prominent in adults than in 
children (61% vs 54%, P<0.0001). Islet autoantibodies 
were measured in the 1778 participants who donated 
an optional blood sample. For individual characteris-
tics, data recording was >98% complete for all variables 
except BMI (and ‘overweight’: 88%) and records of 
having a sibling with diabetes (91%). Data recording for 
diabetes presentation features was >98% complete for all 
variables except symptom duration (94%). Sample sizes 
for incomplete data are reported in the tables. Of the 
total cohort, people of white European origin comprised 
91% (n=3021), Asian (not Chinese) 3% (n=107), Afri-
can-Caribbean 2% (n=63) and other or mixed ethnicity 
3% (n=121). Median time from diagnosis to recruitment 
was 71 days (IQR 40–119) and to blood sampling was 75 
days (IQR 42–126). Of those with body weight measured 
(n=2911), 35% were classified as overweight or obese, 
more commonly in adults than children (41% vs 31%, 
P<0.0001). Where records of body weight were available 
within 28 days of diagnosis (n=554), 35% were also over-
weight or obese (adults 40% vs children 29%, P<0.005).
Data collection for ketoacidosis at diabetes presenta-
tion was based on a record of it being assigned clini-
cally or of hyperglycaemia accompanied by acidosis and 
either ketonaemia or ketonuria. 
the relationships between diabetes presentation and 
individual characteristics
The main presenting features (table 1) were: osmotic 
symptoms (polyuria and/or polydipsia): 96%, weight 
loss: 85%, and fatigue: 82%. Ketoacidosis was identi-
fied at clinical presentation in 42%. Another autoim-
mune disease was present in 6%, 15% had a parent with 
diabetes and 8% had a sibling with diabetes.
The influence of age
Increasing age was independently associated with an 
increased prevalence of ketoacidosis, weight loss and 
fatigue at presentation, decreased prevalence of osmotic 
symptoms and longer symptom duration (figure 1). In 
accord with its relationship with age, ketoacidosis was 
less common in children than adults (39% vs 45%, 
P=0.0002). Although statistically significant, the differ-
ences between children and adults in other presenting 
symptoms were small (osmotic symptoms: 97% vs 95%, 
P=0.001; weight loss: 82% vs 89%, P=0.0001; fatigue: 
78% vs 88%, P=0.0001, respectively), as were differences 
in symptom duration (median, 3 vs 4 weeks, P=0.0001).
The influence of gender
Female sex was independently associated with longer 
symptom duration (figure 1). Median symptom duration 
in females and males were 4 and 3 weeks, respectively 
(P=0.0001).
Associations with ethnicity
There were no significant associations between ethnicity 
and initial clinical presentation, including ketoaci-
dosis, which was equally likely: in white Europeans and 
non-whites (41% and 44%, respectively; P=0.3).
Family history of diabetes
Having a parent with any diabetes was associated with 
a lower probability of presenting with ketoacidosis 
(figure 1; 12% vs 18%, P<0.0001). The same applied to 
Table 1 Clinical and demographic characteristics of the 
cohort (n=3312)
Median (IQR)/
percentage (n)
Individual characteristics
  Age (years) (n=3312) 14.6 (10.4–26.4)
  Male (n=3312) 57 (1879)
  Children (<17 years) (n=3312) 59 (1946)
  Body mass index (n=2911)
   Children (z score, n=1676)* 0.44 (−0.28–1.23)
   Adult (kg/m2, n=1235) 24.1 (21.5–27.1)
  Overweight or obese (n=2911) 35 (1033)
  White European ethnicity (n=3312) 91 (3021)
  Other autoimmune disease present 
(n=3270)
6 (204)
  Parent(s) with any diabetes (n=3261) 15 (499)
  Sibling with any diabetes (n=3003) 8 (229)
Diabetes presentation
  Clinical presentation
   Ketoacidosis (n=3242) 42 (1348)
   Osmotic symptoms (n=3286) 96 (3158)
   Weight loss (n=3251) 85 (2753)
   Fatigue (n=3252) 82 (2682)
  Symptom duration (weeks, n=3105) 3 (2–6)
  Antibody positive (n=1778) 85 (1510)
Sample sizes (n) are given for each variable if data collection was 
incomplete.
*The children’s B MI z-score expressed as a percentile (median 
(IQR)) was 67 % (39%– 89 %) (n = 1676).
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those who had a sibling with diabetes (figure 1; 5% vs 
10%, P<0.0001).
Other autoimmune disease
The presence or absence of another autoimmune disease 
had no significant influence on diabetes presentation.
Description of the cohort in whom autoantibodies were 
measured
Children comprised 38% of the subgroup of 1778 
participants who provided a blood sample for autoanti-
body measurement. The subgroup with blood samples 
was, accordingly, significantly older than the full cohort 
(median (IQR) 21.6 (13.4–32.8) vs 14.6 (10.4–26.4) years, 
P<0.0001). Other parameters were similar. One or more 
autoantibodies were present in 85% of those who donated 
a blood sample.
the relationships between autoantibody status and individual 
characteristics
The influence of age
Autoantibody positivity decreased with increasing age; 
adults were less likely than children to be positive 
for one or more antibodies (82% vs 90%, P<0.0001). 
The decline in autoantibody positivity continued 
Figure 1 Individual characteristics as predictors of diabetes presentation and autoantibody status. Univariate logistic 
regression ORs or linear regression coefficients (circles), 95% CIs (horizontal lines)# and statistical significances are shown. Red 
circles signify that a significant univariate relationship was sustained on multivariable analysis with all individual characteristics 
included as predictor variables (participants with complete data: n=2911–3312) and in the subgroup with antibodies measured 
(participants with complete data including antibody status: n=1610–1778). *Not significant in subgroup with antibodies 
measured on multivariable analysis. **Significant in subgroup with antibodies measured on multivariable analysis. †Not 
significant on multivariable analysis. ††Significant on multivariable analysis. #For ‘Age’, ORs or coefficients and 95% CIs were 
derived from standardised data. DM, diabetes mellitus.
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throughout adult life (figure 2). Of the individual auto-
antibodies, GADAs were the most frequently observed 
in adults, with IA-2A and ZnT8A being relatively more 
common in children (figure 2). The autoantibody-pos-
itive adults were of lower BMI than autoantibody-nega-
tive adults (BMI, median (IQR) 23.9 (21.4–26.7) vs 25.5 
(23.1–29.2), P<0.0001), and they were less likely to be 
overweight or obese (40% vs 55%, P=0.0001). No rela-
tionship to BMI z-score was observed in children, and 
there was no independent relationship between over-
weight/obesity and antibody positivity across children 
and adults (figure 1).
The influence of gender
Females were more likely than males to be antibody posi-
tive (90% vs 82%, respectively (P<0.0001).
Associations with ethnicity
There was a statistically significant relationship between 
ethnicity and autoantibody status (on χ2 analysis, P<0.0001). 
Among the three major non-white ethnic groups (Asian, 
African-Caribbean and other or mixed ethnicity), numbers 
with autoantibodies measured were small (n=46, 36 and 
51, respectively) and the proportion with autoantibody 
positivity did not differ significantly (70%, 64% and 82%, 
respectively; P=0.1). People of non-white ethnic origin were 
therefore grouped, and comparisons were limited to white 
European versus non-white ethnic origin. White Euro-
pean ethnicity was independently associated with a higher 
prevalence of autoantibody positivity compared with the 
combined non-white group (86% and 73%, respectively; 
P<0.0001; figure 1).
Family history of diabetes
People who had a parent with diabetes were less likely 
than those without to have autoantibodies (figure 1; 16% 
vs 28%, P<0.0001, table 2).
Other autoimmune disease
Another autoimmune disease was present in 204 partic-
ipants and 117 of those in whom autoantibodies were 
measured. A history of another autoimmune disease was 
positively associated with pancreatic islet autoantibody 
positivity (P=0.01, figure 1), being present in 8% of the 
autoantibody-positive participants and 4% of the autoan-
tibody-negative participants (table 2).
the relationship between autoantibody status and diabetes 
presentation
A statistically significant relationship between posi-
tive autoantibody status and diabetes presentation 
was restricted to a very small increase in prevalence of 
osmotic symptoms (97% vs 94%, P=0.02, table 2). There 
was no significant difference in rates of ketoacidosis at 
presentation between autoantibody-positive and autoan-
tibody-negative participants (43% vs 40%, P=0.3, table 2).
DIsCussIOn
For the first time, relationships between autoantibody 
status (measured centrally in a single reference labo-
ratory) and phenotypic features in incident T1D are 
reported from a large, unselected, multiethnic popula-
tion of both children and adults. The study was conducted 
with support from the NIHR CRN with most participants 
recruited from specialist centres. Based on estimates of 
T1D incidence and population demographics,23 2420%–
25% of eligible incident cases in England and Wales were 
recruited.
Male predominance is unusual for an autoimmune 
condition but has been reported in adults with incident 
T1D.25 In young children, the sex ratio has been reported 
to be close to unity.26 In the present study, the male excess 
was observed also in children, although the excess was less 
marked than in adults. Symptoms at presentation were as 
Figure 2 The percentage of participants exhibiting islet autoantibodies (any and individual) in relation to age at diagnosis. 
GAD, glutamate decarboxylase; IA2, islet antigen-2; ZnT8, zinc transporter 8.
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expected.27 28 Although weight loss was common, average 
body weight at the time of recruitment was normal, and 
many participants were overweight or obese, especially 
adults. This was apparent even in people with body weight 
measurements obtained within 28 days of diagnosis, 
belying the belief that patients presenting with T1D are 
underweight. An association between increased BMI and 
increased risk of progression from autoantibody positivity 
to development of diabetes in at-risk relatives has been 
reported previously.29 Symptom duration was similar to 
that reported previously by others and was shorter in chil-
dren than adults.30 31 This may reflect parental vigilance 
of unwell children or a more insidious onset of clinical 
disease in older people.
The overall frequency of ketoacidosis at diagnosis (42%) 
was high and slightly more so in adults than children. It 
occurred with similar frequency in white European and 
non-white ethnic groups. The figure of 42% is higher than 
in previous reports from the UK (23% in a recent national 
paediatric audit,32 26%–27% in regional studies33 34), and 
a range of 13%–80% in those aged <20 years has been 
reported internationally.35 A very similar figure (40.3%) 
has been reported recently for children in Italy.36 Keto-
acidosis at diagnosis is a quality issue as it reflects lack of 
awareness of diabetes features among professionals and 
the general population,32 and efforts to increase aware-
ness lead to reductions in ketoacidosis at first presen-
tation.37 All methods of estimating the frequency of 
ketoacidosis at diagnosis have limitations, often leading to 
under-reporting.32 Strengths of the current study include 
the large number of patients and the ability to confirm or 
refute the diagnosis where this was in doubt. A limitation 
is that ascertainment bias could be introduced because 
recruitment was mainly from secondary care, and those 
who are the most ill at diagnosis may be the most likely 
to volunteer or to be referred. The higher ketoacidosis 
rate in adults versus children in our study appears at 
variance with the observation that ketoacidosis or severe 
ketoacidosis is more common in younger than in older 
children.28 33 36 38–40 The current study did not include 
children <5 years of age, the group in childhood in 
whom ketoacidosis at diagnosis occurs most frequently,41 
and this may have contributed to the apparent children 
to adult difference. Of course, if such younger children 
had been included, this could have increased the overall 
rate of ketoacidosis even higher. The lower rate associ-
ated with having a parent or a sibling with diabetes could 
result from a heightened awareness of symptoms leading 
to earlier clinical referral.35 The absence of any signifi-
cant ethnic influence on ketoacidosis is at variance with 
Table 2 Characteristics of pancreatic autoantibody (Ab) positive and negative participants (n=1778 with known antibody 
status)
Ab positive (n=1510) Ab negative (n=268) P values
Individual characteristics
  Age 20.1 (13.1–31.1) 31.4 (17.7–41.0) 0.0001
  Male 56 (851) 72 (192) <0.0001
  Children 41 (614) 25 (66) <0.0001
  Body mass index
   Children (z score, n=545, 56)* 0.41 (−0.35 to 1.19) 0.47 (−0.48 to 0.97) 0.4
   Adult (kg/m2, n=825, 184) 23.9 (21.4–26.7) 25.5 (23.1–29.2) 0.0001
  Overweight (n=1370, 240) 36 (490) 48 (114) 0.0005
  White European ethnicity 86 (1413) 14 (232) <0.0001
  Other autoimmune disease (n=1495, 265) 8 (117) 4 (10) 0.01
  Parent(s) with any diabetes (n=1493, 261) 16 (233) 28 (74) <0.0001
  Siblings with any diabetes (n=1374, 238) 9 (117) 8 (20) 0.9
Diabetes presentation
  Clinical presentation
   Ketoacidosis (n=1483, 260) 43 (639) 40 (104) 0.3
   Osmotic symptoms (n=1495, 267) 97 (1444) 94 (250) 0.02
   Weight loss (n=1480, 267) 87 (1285) 88 (235) 0.5
   Fatigue (n=1490, 265) 86 (1282) 80 (213) 0.01
  Symptom duration (weeks, n=1424, 246)** 6.8 (10.5) 10.4 (32.2) 0.004
Percentages (n) or medians (IQR) are shown. 
Sample sizes (n) are given for each variable if data collection was incomplete.
*The children's BMI z-scores expressed as percentiles (median (IQR)) were 66% (36%-88%) in the autoantibody positive (n=545) and 68% 
(32%-83%) in the autoantibody negative (n=56).
**Median and IQRs for symptom duration were identical: 4 (2–8); mean and SD is shown to clarify the direction of difference.
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some previous reports where higher rates were observed 
in non-white subgroups.42 43
One or more islet autoantibodies were observed in 85% 
of participants, more commonly in female than male 
and in younger compared with older participants. This 
is compatible with previous literature from the UK and 
other countries,8 44–46 although assay differences make 
such comparisons difficult. The positivity rate is higher 
than reported in people with T1D of non-white ethnic 
origin,12 13although with the same caveats and bearing 
in mind that the previous studies of ethnic influences 
on antibody status have been limited in size or age range 
of population studied. The slight female autoantibody 
preponderance has been observed in other studies in 
young children, but not in older children and young 
adults.47 The higher autoantibody frequency in those 
with a coexistent autoimmune disease reflects the clus-
tering of autoimmune disorders observed in T1D and 
shared genetic susceptibility.48 Overall, GADAs were the 
antibodies most commonly present, while IA-2A and 
ZnT8A were seen most frequently in children, findings 
compatible with previous studies.47 Insulin itself is consid-
ered a potential primary autoantigen as insulin auto-
antibodies are observed in incident T1D, especially in 
children.30 31 49 In the current study, most participants had 
received insulin therapy for weeks before study entry, and 
as they could have developed antibodies to the exogenous 
insulin, insulin autoantibodies were not measured. In 
prospective studies of infants at high genetic risk of T1D, 
insulin autoantibodies were often detected earlier than 
the other islet autoantibodies,50 51 and in consequence, 
we may have underestimated the frequency of autoanti-
body positivity at diagnosis, especially in children.
Although autoantibodies can be present for years in 
people with diabetes who do not require insulin treatment 
immediately52–54 and are present in some diagnosed clini-
cally with type 2 diabetes,55 they are generally regarded as 
a biomarker for T1D. In prospective studies they precede 
and predict the onset of T1D.56 They typically disappear, 
or titres drop to very low levels, in the years following 
diagnosis.57 In the autoantibody-negative participants 
studied here, several explanations may be proposed. 
First, insulin autoantibodies were not measured. Second, 
autoantibodies to as yet unknown antigens may have been 
present.58 The identification of tetraspanin-7 as an auto-
antigen could, for example, account for some apparently 
antibody-negative participants,59 although recent data 
suggest this is unlikely to account for large numbers.60 
Third, autoantibodies may have disappeared or their 
levels diminished by the time of sampling. As all partic-
ipants were recruited within 6 months of diagnosis, this 
is unlikely to be a major factor. Fourth, autoantibodies 
might develop subsequently, as reported previously for 
islet cell antibodies in a small proportion of patients.61 
Fifth, some people may have autoimmune T1D without 
a humoural response. Finally, people may actually have 
another diabetes subtype. The autoantibody-negative 
participants as a group tended to be older and, if adult, 
more overweight. These features are compatible with 
type 2 diabetes. They were more likely to have a parent 
with diabetes, typical of type 2 or monogenic diabetes. 
They were more likely to be of non-white ethnicity, more 
associated with type 2 diabetes. Those with ketoacidosis 
could have ketosis-prone diabetes (so-called idiopathic 
diabetes)62 as this is difficult to distinguish from T1D at 
first presentation. Further studies and follow-up of the 
cohort are planned to explore the extent to which T1D 
without detectable autoantibodies describes a subgroup 
of T1D that is distinct from other diabetes subtypes.
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